STOCK TITAN
  1. Home
  2. CALTX

Six Circles Multi-Strategy (CALTX) Stock Price, News & Analysis

CALTX
Published by Stock Titan Data refreshed

What Changed

Company Description

This page collects what Stock Titan holds for CALTX, including price data and latest news.

Stock Performance

Chart
$—
-
-
Last updated:
-
Performance 1 year
-
Market Cap
-
Shares outstanding

Latest News

View All
0.00%

Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy

0.00%

Calliditas provides setanaxib patent update

0.00%

Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy

0.00%

Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress

0.00%

Calliditas Q1 report, January - March 2024

earnings
0.00%

In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action

0.00%

Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm

conferences
0.00%

Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China

0.00%

Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

clinical trial
0.00%

Calliditas Therapeutics' 2023 Annual Report Published

Six Circles Multi-Strategy has 10 recent news articles. Key topics include earnings, conferences, clinical trial. View all CALTX news →

SEC Filings

View All

No SEC filings available for CALTX.